APTIOM
APTIOM is an antiepileptic medication indicated for the treatment of partial-onset seizures. It is approved for use in a broad patient population, including adults and pediatric patients aged 4 years and older. The medication provides a therapeutic option for managing seizure activity in these individuals.
How APTIOM Works
APTIOM is extensively converted into its active metabolite, eslicarbazepine, which is responsible for the drug's therapeutic effects. While the precise mechanism of action is not fully established, it is thought to involve the inhibition of voltage-gated sodium channels. By interacting with these channels, the drug is believed to exert the anticonvulsant activity necessary to manage seizures.
Details
- Status
- Prescription
- First Approved
- 2013-11-08
- Routes
- ORAL
- Dosage Forms
- TABLET
APTIOM Approval History
What APTIOM Treats
1 indicationsAPTIOM is approved for 1 conditions since its original approval in 2013. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Partial-Onset Seizures
Drugs Similar to APTIOM
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
APTIOM FDA Label Details
ProIndications & Usage
FDA Label (PDF)APTIOM is indicated for the treatment of partial-onset seizures in patients 4 years of age and older. APTIOM is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.